138 related articles for article (PubMed ID: 38197296)
1. Xevinapant plus radiotherapy in resected, high-risk, cisplatin-ineligible LA SCCHN: the phase III XRay Vision study design.
Ferris RL; Mehanna H; Schoenfeld JD; Tahara M; Yom SS; Haddad R; König A; Witzler P; Bajars M; Tourneau CL
Future Oncol; 2024 Apr; 20(12):739-748. PubMed ID: 38197296
[TBL] [Abstract][Full Text] [Related]
2. Xevinapant or placebo plus chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck: TrilynX phase III study design.
Bourhis J; Burtness B; Licitra LF; Nutting C; Schoenfeld JD; Omar M; Bouisset F; Nauwelaerts H; Urfer Y; Zanna C; Cohen EE
Future Oncol; 2022 May; 18(14):1669-1678. PubMed ID: 35172587
[TBL] [Abstract][Full Text] [Related]
3. Long-term results from a clinical study of xevinapant plus chemoradiotherapy in people with high-risk locally advanced squamous cell carcinoma of the head and neck: a plain language summary.
Tao Y; Sun XS; Pointreau Y; Tourneau CL; Sire C; Gollmer K; Crompton P; Bourhis J
Future Oncol; 2023 Aug; 19(26):1769-1776. PubMed ID: 37439181
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the inhibitors: Development of the IAP inhibitor xevinapant for the treatment of locally advanced squamous cell carcinoma of the head and neck.
Ferris RL; Harrington K; Schoenfeld JD; Tahara M; Esdar C; Salmio S; Schroeder A; Bourhis J
Cancer Treat Rev; 2023 Feb; 113():102492. PubMed ID: 36640618
[TBL] [Abstract][Full Text] [Related]
5. Extended follow-up of a phase 2 trial of xevinapant plus chemoradiotherapy in high-risk locally advanced squamous cell carcinoma of the head and neck: a randomised clinical trial.
Tao Y; Sun XS; Pointreau Y; Le Tourneau C; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Calderon B; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Damstrup L; Crompton P; Ennaji A; Gollmer K; Nauwelaerts H; Bourhis J
Eur J Cancer; 2023 Apr; 183():24-37. PubMed ID: 36796234
[TBL] [Abstract][Full Text] [Related]
6. Managing cisplatin-ineligible patients with resected, high-risk, locally advanced squamous cell carcinoma of the head and neck: Is there a standard of care?
Haddad RI; Harrington K; Tahara M; Szturz P; Le Tourneau C; Salmio S; Bajars M; Lee NY
Cancer Treat Rev; 2023 Sep; 119():102585. PubMed ID: 37392723
[TBL] [Abstract][Full Text] [Related]
7. Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Vugmeyster Y; Ravula A; Rouits E; Diderichsen PM; Kleijn HJ; Koenig A; Wang X; Schroeder A; Goteti K; Venkatakrishnan K
Clin Pharmacol Ther; 2024 Jan; 115(1):52-61. PubMed ID: 37777832
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
9. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer.
Hitt R; Mesía R; Lozano A; Iglesias Docampo L; Grau JJ; Taberna M; Rubió-Casadevall J; Martínez-Trufero J; Morillo EDB; García Girón C; Vázquez Estévez S; Cirauqui B; Cruz-Hernández JJ
Oral Oncol; 2022 Nov; 134():106087. PubMed ID: 36126605
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).
Prawira A; Brana-Garcia I; Spreafico A; Hope A; Waldron J; Razak AR; Chen EX; Jang R; O'Sullivan B; Giuliani M; Bayley A; Cho J; Wang L; Perez-Ordonez B; Weinreb I; Siu LL; Hansen AR
Invest New Drugs; 2016 Oct; 34(5):575-83. PubMed ID: 27289242
[TBL] [Abstract][Full Text] [Related]
11. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Lee NY; Ferris RL; Psyrri A; Haddad RI; Tahara M; Bourhis J; Harrington K; Chang PM; Lin JC; Razaq MA; Teixeira MM; Lövey J; Chamois J; Rueda A; Hu C; Dunn LA; Dvorkin MV; De Beukelaer S; Pavlov D; Thurm H; Cohen E
Lancet Oncol; 2021 Apr; 22(4):450-462. PubMed ID: 33794205
[TBL] [Abstract][Full Text] [Related]
12. Debio 1143 and high-dose cisplatin chemoradiotherapy in high-risk locoregionally advanced squamous cell carcinoma of the head and neck: a double-blind, multicentre, randomised, phase 2 study.
Sun XS; Tao Y; Le Tourneau C; Pointreau Y; Sire C; Kaminsky MC; Coutte A; Alfonsi M; Boisselier P; Martin L; Miroir J; Ramee JF; Delord JP; Clatot F; Rolland F; Villa J; Magne N; Elicin O; Gherga E; Nguyen F; Lafond C; Bera G; Calugaru V; Geoffrois L; Chauffert B; Zubel A; Zanna C; Brienza S; Crompton P; Rouits E; Gollmer K; Szyldergemajn S; Bourhis J
Lancet Oncol; 2020 Sep; 21(9):1173-1187. PubMed ID: 32758455
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin.
Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341
[TBL] [Abstract][Full Text] [Related]
14. Sequential chemotherapy regimen of induction with panitumumab and paclitaxel followed by radiotherapy and panitumumab in patients with locally advanced head and neck cancer unfit for platinum derivatives. The phase II, PANTERA/TTCC-2010-06 study.
Martínez-Trufero J; Lozano Borbalas A; Pajares Bernad I; Taberna Sanz M; Ortega Izquierdo E; Cirauqui Cirauqui B; Rubió-Casadevall J; Plana Serrahima M; Ponce Ortega JM; Planas Toledano I; Caballero J; Marruecos Querol J; Iglesias Docampo L; Lambea Sorrosal J; Adansa JC; Mesía Nin R;
Clin Transl Oncol; 2021 Aug; 23(8):1666-1677. PubMed ID: 33876416
[TBL] [Abstract][Full Text] [Related]
15. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial.
Caponigro F; Di Gennaro E; Ionna F; Longo F; Aversa C; Pavone E; Maglione MG; Di Marzo M; Muto P; Cavalcanti E; Petrillo A; Sandomenico F; Maiolino P; D'Aniello R; Botti G; De Cecio R; Losito NS; Scala S; Trotta A; Zotti AI; Bruzzese F; Daponte A; Calogero E; Montano M; Pontone M; De Feo G; Perri F; Budillon A
BMC Cancer; 2016 Nov; 16(1):918. PubMed ID: 27884140
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel, cisplatin and 5-FU compared with docetaxel, cisplatin and cetuximab as induction chemotherapy in advanced squamous cell carcinoma of the head and neck: Results of a randomised phase II AGMT trial.
Keil F; Hartl M; Altorjai G; Berghold A; Riedl R; Pecherstorfer M; Mayrbäurl B; De Vries A; Schuster J; Hackl J; Füreder T; Melchardt T; Burian M; Greil R
Eur J Cancer; 2021 Jul; 151():201-210. PubMed ID: 34022697
[TBL] [Abstract][Full Text] [Related]
18. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
[TBL] [Abstract][Full Text] [Related]
19. Novel approach of prophylactic radiation to reduce toxicities comparing 2-step40 with 56-Gy simultaneous integrated boost intensity-modulated radiation therapy for locally advanced squamous cell carcinoma of the head and neck, an intergroup phase III trial (JCOG1912, NEW BRIDGE).
Yokota T; Zenda S; Kodaira T; Kiyota N; Fujimoto Y; Wasano K; Takahashi R; Mizowaki T; Homma A; Sasaki K; Machida R; Sekino Y; Fukuda H; ;
BMC Cancer; 2023 Nov; 23(1):1068. PubMed ID: 37932681
[TBL] [Abstract][Full Text] [Related]
20. Weekly Cisplatin Plus Radiation for Postoperative Head and Neck Cancer (JCOG1008): A Multicenter, Noninferiority, Phase II/III Randomized Controlled Trial.
Kiyota N; Tahara M; Mizusawa J; Kodaira T; Fujii H; Yamazaki T; Mitani H; Iwae S; Fujimoto Y; Onozawa Y; Hanai N; Ogawa T; Hara H; Monden N; Shimura E; Minami S; Fujii T; Tanaka K; Homma A; Yoshimoto S; Oridate N; Omori K; Ueda T; Okami K; Ota I; Shiga K; Sugasawa M; Asakage T; Saito Y; Murono S; Nishimura Y; Nakamura K; Hayashi R;
J Clin Oncol; 2022 Jun; 40(18):1980-1990. PubMed ID: 35230884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
